Catheter ablation treatment for atrial fibrillation

S4 Medical has developed the esolution® device, which is the first and only FDA-cleared technology designed to deviate the esophagus during ablation procedures for atrial fibrillation. This innovative device addresses a significant concern in electrophysiology, as esophageal injuries related to ablation can occur in up to 47% of patients. The esolution device operates by utilizing vacuum suction to create bilateral deviation of the esophagus, allowing for safer ablation near the pulmonary veins. This capability enables electrophysiologists to tailor the deviation based on individual patient anatomy and lesion strategies, thereby enhancing the safety and efficacy of the ablation process.

The esolution device is compatible with any ablation energy source and does not require additional hardware or software, streamlining the catheter ablation workflow. It is designed to work seamlessly with existing mapping systems and temperature probes, ensuring that it integrates smoothly into current clinical practices. The benefits of using esolution include a reduction in radiofrequency (RF) time by 18%, a significant decrease in interruptions due to temperature increases, and an 84% reduction in thermal injuries. This combination of features positions esolution as a vital tool for improving patient outcomes in atrial fibrillation ablation procedures.

United States

S4 Medical is committed to developing solutions for safer and more effective catheter ablation treatment for atrial fibrillation.

S4 Medical

Company Details